[8-K] Teladoc Health, Inc. Reports Material Event

Rhea-AI Filing Summary

Atlassian (TEAM) Form 4: CEO, co-founder and 10% owner Michael Cannon-Brookes sold a total of 7,765 Class A shares on 22 Jul 2025 under a pre-arranged Rule 10b5-1 plan adopted 20 Feb 2025.

The stock was disposed of in seven separate trades at weighted-average prices between $195.965 and $202.35, generating roughly $1.55 million in gross proceeds. Following the sales, the insider—through CBC Co Pty Ltd as trustee of the Cannon-Brookes Head Trust—continues to hold 375,585 Class A shares, maintaining more than 98% of his prior indirect position and his 10% beneficial-owner status.

No derivative activity or purchases were reported. Given the modest 2% reduction in holdings and the existence of a 10b5-1 plan, the transactions appear routine and are unlikely to materially alter insider alignment, though any CEO liquidation can create short-term sentiment pressure.

Positive

• Sale executed under a Rule 10b5-1 plan, reducing concerns about opportunistic timing.
• Insider retains 375,585 shares, maintaining substantial equity alignment with shareholders.

Negative

• CEO liquidated 7,765 shares worth ≈$1.55 m, which could cause minor negative sentiment.
• No offsetting insider purchases were disclosed in the period.

Insights

Financial Analyst

TL;DR: Small, pre-planned CEO sale; negligible impact on ownership or thesis.

The 7,765-share sale represents ~2% of Cannon-Brookes’ stake and less than 0.3% of daily TEAM volume, limiting market impact. Proceeds of ~$1.55 m are immaterial relative to his remaining ~$75 m holding. Executed under a February-adopted 10b5-1 plan, the transaction reduces signaling risk. From a valuation standpoint, the filing does not change cash flow, guidance, or strategic outlook; therefore I view the development as neutral.

Corporate Governance Expert

TL;DR: Governance-compliant sale; insider still strongly aligned.

The filing demonstrates adherence to SEC Rule 10b5-1 best practices, with full price ranges disclosed and trustee ownership clarified. Retention of 375,585 shares preserves significant skin-in-the-game, supporting shareholder alignment. While any director sale draws attention, the minimal size and structured plan suggest routine liquidity rather than adverse insider insight. I classify the event as governance-neutral.

FALSE000147744900014774492025-07-172025-07-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 17, 2025

___________________________________

Teladoc Health, Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware (State or other jurisdiction of incorporation)			001-37477 (Commission File Number)			04-3705970 (I.R.S. Employer Identification No.)
155 E 44th Street Floor 17 New York, NY 10017
(Address of principal executive offices and zip code)
(203) 635-2002

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol			Name of each exchange on which registered
Common stock, par value $0.001 per share			TDOC			The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01    Entry into a Material Definitive Agreement.

On July 17, 2025 (the “Effective Date”), Teladoc Health, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Administrative Agent”), issuing bank and swingline lender, and the lenders party thereto. The Credit Agreement provides for a five-year, $300 million senior secured revolving credit facility (the “Revolving Credit Facility”).

The Company entered into the Revolving Credit Facility to preserve and enhance its financial and operational flexibility, and it does not currently anticipate borrowing any amounts under the Revolving Credit Facility. The Company’s capital allocation priorities remain unchanged and include: (i) maintaining a strong balance sheet and an appropriate net leverage profile; (ii) investing in the business to support its strategy through both organic and inorganic initiatives; and (iii) evaluating share repurchases as a potential use of excess cash.

Interest rates under the Revolving Credit Facility are variable and are equal to the euro interbank offered rate, the Sterling Overnight Index Average Reference Rate, the Secured Overnight Financing Rate (“Adjusted Term SOFR”) or the Canadian Overnight Repo Rate Average, in each case, plus a margin of 2.75% to 3.25% per annum based on the Company’s secured net leverage ratio, or, at the Company’s option, at a base reference rate equal to the highest of (a) the federal funds rate plus 0.50%, (b) the rate of interest last quoted by the Administrative Agent as its “base rate” and (c) the one-month Adjusted Term SOFR plus 1.00%, plus a margin of 1.75% to 2.25% per annum based on the Company’s secured net leverage ratio.

The Company will pay customary agency fees and a commitment fee based on the daily unused portion of the Revolving Credit Facility at a rate of 0.50% per annum. The Revolving Credit Facility is not subject to amortization and will mature on the fifth anniversary of the Effective Date.

The Company’s obligations under the Credit Agreement are unconditionally guaranteed by all material domestic and foreign wholly-owned subsidiaries of the Company (the “Subsidiary Guarantors” and together with the Company, the “Obligors”), with customary exceptions.

On the Effective Date, each of the Obligors and the Administrative Agent entered into a pledge and security agreement, pursuant to which the Obligors granted a security interest in substantially all of their respective assets, in each case, subject to customary exceptions and exclusions.

The Credit Agreement contains customary representations and warranties, affirmative covenants, negative covenants and events of default. The Credit Agreement also contains financial covenants that are tested on the last day of each of the Company’s fiscal quarters. These financial covenants include a (x) maximum secured net leverage ratio of 3.50:1.00, subject to a 4.00:1.00 covenant holiday following certain permitted acquisitions or permitted collaborations, and (y) minimum consolidated interest coverage ratio of 3.00:1.00.

The foregoing description of the Credit Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Credit Agreement, attached hereto as Exhibit 10.1 and incorporated herein by reference.

Item 2.03    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 by reference.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
10.1						Credit Agreement, dated July 17, 2025, among Teladoc Health, Inc., JPMorgan Chase Bank, N.A., as administrative agent, issuing bank and swingline lender, and the lenders party thereto.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 23, 2025

Teladoc Health, Inc.
By:			/s/ Adam C. Vandervoort
Name:			Adam C. Vandervoort
Title:			Chief Legal Officer and Secretary

FAQ

How many Atlassian (TEAM) shares did CEO Michael Cannon-Brookes sell?

He sold 7,765 Class A shares on 22 Jul 2025.

What was the average sale price reported in the Form 4?

Weighted-average prices ranged from $195.965 to $202.35 per share.

How many TEAM shares does the insider still own after the transactions?

Cannon-Brookes indirectly holds 375,585 Class A shares through a trust.

Was the insider sale executed under a 10b5-1 trading plan?

Yes, the plan was adopted on 20 Feb 2025.

Did the filing report any derivative security transactions?

No; Table II shows no derivative activity.

What percentage of the insider’s holdings were sold?

Approximately 2% of his previous indirect stake.